S&P 500   4,335.01 (-1.53%)
DOW   34,102.38 (-0.98%)
QQQ   358.69 (-1.60%)
AAPL   174.34 (-0.66%)
MSFT   321.12 (+0.11%)
META   297.08 (-0.86%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.50 (-3.63%)
BABA   84.21 (-1.78%)
AMD   96.09 (-4.24%)
T   15.32 (-1.48%)
F   12.19 (-1.38%)
MU   68.14 (-2.21%)
CGC   0.78 (-10.99%)
GE   113.26 (-1.38%)
DIS   82.80 (+0.29%)
AMC   7.72 (-5.39%)
PFE   32.87 (-2.23%)
PYPL   58.89 (-3.24%)
NFLX   384.05 (-0.58%)
S&P 500   4,335.01 (-1.53%)
DOW   34,102.38 (-0.98%)
QQQ   358.69 (-1.60%)
AAPL   174.34 (-0.66%)
MSFT   321.12 (+0.11%)
META   297.08 (-0.86%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.50 (-3.63%)
BABA   84.21 (-1.78%)
AMD   96.09 (-4.24%)
T   15.32 (-1.48%)
F   12.19 (-1.38%)
MU   68.14 (-2.21%)
CGC   0.78 (-10.99%)
GE   113.26 (-1.38%)
DIS   82.80 (+0.29%)
AMC   7.72 (-5.39%)
PFE   32.87 (-2.23%)
PYPL   58.89 (-3.24%)
NFLX   384.05 (-0.58%)
S&P 500   4,335.01 (-1.53%)
DOW   34,102.38 (-0.98%)
QQQ   358.69 (-1.60%)
AAPL   174.34 (-0.66%)
MSFT   321.12 (+0.11%)
META   297.08 (-0.86%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.50 (-3.63%)
BABA   84.21 (-1.78%)
AMD   96.09 (-4.24%)
T   15.32 (-1.48%)
F   12.19 (-1.38%)
MU   68.14 (-2.21%)
CGC   0.78 (-10.99%)
GE   113.26 (-1.38%)
DIS   82.80 (+0.29%)
AMC   7.72 (-5.39%)
PFE   32.87 (-2.23%)
PYPL   58.89 (-3.24%)
NFLX   384.05 (-0.58%)
S&P 500   4,335.01 (-1.53%)
DOW   34,102.38 (-0.98%)
QQQ   358.69 (-1.60%)
AAPL   174.34 (-0.66%)
MSFT   321.12 (+0.11%)
META   297.08 (-0.86%)
GOOGL   130.68 (-2.29%)
AMZN   129.76 (-4.09%)
TSLA   257.09 (-2.09%)
NVDA   410.77 (-2.75%)
NIO   8.50 (-3.63%)
BABA   84.21 (-1.78%)
AMD   96.09 (-4.24%)
T   15.32 (-1.48%)
F   12.19 (-1.38%)
MU   68.14 (-2.21%)
CGC   0.78 (-10.99%)
GE   113.26 (-1.38%)
DIS   82.80 (+0.29%)
AMC   7.72 (-5.39%)
PFE   32.87 (-2.23%)
PYPL   58.89 (-3.24%)
NFLX   384.05 (-0.58%)
NASDAQ:GEVO

Gevo (GEVO) Stock Forecast, Price & News

$1.21
-0.07 (-5.47%)
(As of 03:34 PM ET)
Compare
Today's Range
$1.21
$1.29
50-Day Range
$1.28
$1.77
52-Week Range
$1.01
$2.58
Volume
2.86 million shs
Average Volume
5.44 million shs
Market Capitalization
$287.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.79

Gevo MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
286.3% Upside
$4.79 Price Target
Short Interest
Bearish
15.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$799,055 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.26) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Oils/Energy Sector

186th out of 237 stocks

Industrial Organic Chemicals Industry

14th out of 19 stocks


GEVO stock logo

About Gevo (NASDAQ:GEVO) Stock

Gevo, Inc. operates as a renewable fuels company. It operates through three segments: Gevo, Agri-Energy, and Renewable Natural Gas. The company offers renewable gasoline and diesel, isooctane, isobutanol, sustainable aviation fuel, renewable natural gas, isobutylene, ethanol, and animal feed and protein. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was incorporated in 2005 and is headquartered in Englewood, Colorado.

GEVO Price History

GEVO Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
H.C. Wainwright Remains a Buy on Gevo (GEVO)
Gevo gets $30M grant from USDA
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Gevo Reports Second Quarter 2023 Financial Results
Gevo (GEVO) Receives a Rating Update from a Top Analyst
See More Headlines
Receive GEVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gevo and its competitors with MarketBeat's FREE daily newsletter.

GEVO Company Calendar

Last Earnings
8/10/2023
Today
9/21/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:GEVO
CUSIP
37439610
Fax
N/A
Employees
87
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$4.79
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+268.8%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-98,010,000.00
Net Margins
-1,105.89%
Pretax Margin
-1,105.89%

Debt

Sales & Book Value

Annual Sales
$1.17 million
Book Value
$2.55 per share

Miscellaneous

Free Float
228,975,000
Market Cap
$308.31 million
Optionable
Optionable
Beta
3.12

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Patrick R. Gruber M.B.A.Dr. Patrick R. Gruber M.B.A. (Age 62)
    MBA, Ph.D., CEO & Director
    Comp: $926.15k
  • Dr. Christopher M. RyanDr. Christopher M. Ryan (Age 62)
    Pres & COO
    Comp: $570.62k
  • Mr. L. Lynn Smull (Age 62)
    Chief Financial Officer
    Comp: $477k
  • Mr. Timothy J. Cesarek (Age 59)
    Chief Commercial Officer
    Comp: $477k
  • Dr. Paul D. Bloom (Age 49)
    Chief Carbon Officer & Chief Innovation Officer
    Comp: $432k
  • Prof. James C. Liao Ph.D.
    Co-Founder
  • Mr. Alisher Nurmat CPA (Age 53)
    Principal Accounting Officer, VP & Controller
  • Ms. Heather L. Manuel
    VP of Corp. Communications
  • Ms. Kimberly T. Bowron SPHR (Age 53)
    Chief People Officer
  • Mr. David A. George
    Sr. VP of Verity Tracking













GEVO Stock - Frequently Asked Questions

Should I buy or sell Gevo stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gevo in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GEVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GEVO, but not buy additional shares or sell existing shares.
View GEVO analyst ratings
or view top-rated stocks.

What is Gevo's stock price forecast for 2023?

5 brokerages have issued 1-year price objectives for Gevo's stock. Their GEVO share price forecasts range from $2.00 to $14.00. On average, they anticipate the company's share price to reach $4.79 in the next year. This suggests a possible upside of 268.8% from the stock's current price.
View analysts price targets for GEVO
or view top-rated stocks among Wall Street analysts.

How have GEVO shares performed in 2023?

Gevo's stock was trading at $1.90 at the beginning of 2023. Since then, GEVO stock has decreased by 31.6% and is now trading at $1.2987.
View the best growth stocks for 2023 here
.

When is Gevo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our GEVO earnings forecast
.

How were Gevo's earnings last quarter?

Gevo, Inc. (NASDAQ:GEVO) issued its quarterly earnings results on Thursday, August, 10th. The energy company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06). The energy company had revenue of $4.24 million for the quarter, compared to the consensus estimate of $4.39 million. Gevo had a negative net margin of 1,105.89% and a negative trailing twelve-month return on equity of 16.82%. During the same period in the prior year, the company earned ($0.06) earnings per share.

When did Gevo's stock split?

Shares of Gevo reverse split on Monday, June 4th 2018. The 1-20 reverse split was announced on Friday, June 1st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 1st 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Patrick Gruber's approval rating as Gevo's CEO?

7 employees have rated Gevo Chief Executive Officer Patrick Gruber on Glassdoor.com. Patrick Gruber has an approval rating of 15% among the company's employees. This puts Patrick Gruber in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gevo own?
What is Gevo's stock symbol?

Gevo trades on the NASDAQ under the ticker symbol "GEVO."

Who are Gevo's major shareholders?

Gevo's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.13%), State Street Corp (4.99%), Geode Capital Management LLC (1.94%), Northern Trust Corp (0.80%), Baird Financial Group Inc. (0.69%) and Nuveen Asset Management LLC (0.38%). Insiders that own company stock include Alisher K Nurmat, Andrew Marsh, Christopher Michael Ryan, Gary W Mize, Geoffrey Thomas Jr Williams, Kimberly T Bowron, L Lynn Smull, Patrick R Gruber, Paul D Bloom and Timothy J Cesarek.
View institutional ownership trends
.

How do I buy shares of Gevo?

Shares of GEVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gevo's stock price today?

One share of GEVO stock can currently be purchased for approximately $1.30.

How much money does Gevo make?

Gevo (NASDAQ:GEVO) has a market capitalization of $308.31 million and generates $1.17 million in revenue each year. The energy company earns $-98,010,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact Gevo?

Gevo's mailing address is 345 Inverness Drive South Building C Suite 310, Englewood CO, 80112. The official website for the company is www.gevo.com. The energy company can be reached via phone at (303) 858-8358 or via email at info@integra-ir.com.

This page (NASDAQ:GEVO) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -